Enhanced Biosafety Level 2 (BSL-2+) Guidance

This page outlines general guidance to be followed when laboratory activities have been approved by the Boston University (BU) Institutional Biosafety Committee (IBC) for BSL-2+ containment. Additional requirements may apply based on the risk assessment of individual agent and procedures. In general, BSL-2+ builds upon BSL-2 practices with the following minimal additions: Modified PPE. Double […]

Research Compliance Guidance on the Use of SARS-CoV-2 Variants

BACKGROUND AND PURPOSE The causative agent for the current COVID-19 pandemic is a coronavirus designated as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Coronaviruses are enveloped, positive sense RNA viruses whose genomes range from 25 to 35 Kb in size. At least seven species of these viruses are known to cause human diseases. However, despite […]

Guidance and Recommended Practices for Working with Inactivated SARS-COV-2 Materials

BACKGROUND & PURPOSE Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) is a newly identified viral pathogen that causes the disease COVID-19 (novel Coronavirus Disease-2019). SARS CoV‐2 is a positive strand, or sense strand, single-stranded RNA virus. SARS‐CoV-2 is highly infectious and has affected millions of people worldwide resulting in a pandemic.  Boston University has […]

2019 IBC Public Meeting Announced

The Institutional Biosafety Committee (IBC) of Boston University will hold its annual public meeting on Tuesday, September 17, 2019, from 12 – 3:00 pm at the Boston University School of Medicine, 650 Albany Street, in X-714/715 Conference Room, 7th Floor, Boston, Massachusetts 02118. The IBC is an institutional committee created under NIH guidelines to review […]

Information For...

Back to Top